Abstract
Obesity is associated with chronic inflammation in insulin‐sensitive tissues, including liver and adipose tissue, and causes hormonal/metabolic complications, such as insulin resistance. There is growing evidence that peripheral cannabinoid‐type 1 receptor (CB1R) is a crucial participant in obesity‐induced pro‐inflammatory responses in insulin‐target tissues, and its selective targeting could be a novel therapeutic strategy to break the link between insulin resistance and metabolic inflammation. In this review, we introduce the role of peripheral CB1R in metabolic inflammation and as a mediator of hormonal/metabolic complications that underlie metabolic syndrome, including fatty liver, insulin resistance, and dyslipidemia. We also discuss the therapeutic potential of second‐ and third‐generation peripherally restricted CB1R antagonists for treating obesity‐induced metabolic inflammation without eliciting central CB1R‐mediated neurobehavioral effects, predictive of neuropsychiatric side effects, in humans.
Funding Information
  • National Research Foundation of Korea (2019R1A6A1A11051471, 2019R1A2B5B03100464, 2019R1I1A1A01061122)

This publication has 96 references indexed in Scilit: